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Abstract
BACKGROUND: Clinical manifestation of coronavirus disease (COVID-19) could be asymptomatic, mild to severe, 
even mortality. Although various hematological complications associated with COVID-19 infection have been 
reported, the finding of autoimmune hemolytic anemia (AIHA) is a novel case. 
CASE REPORT: A 59-year-old woman was admitted to our emergency room because of a 5-day period of fever with 
cough and shortness of breath. At admission, she was takipnea, jaundice, and had an oxygen saturation of 60% on 
room air. Laboratory studies showed hemoglobin (Hb) 3.68 g/dL, high reticulocyte (14.4%), and hyperbilirubinemia. 
Chest X-ray showed bilateral pneumonia with positive severe acute respiratory syndrome coronavirus 2 polymerase 
chain reaction test. Although she got packed red cell (PRC) transfusions in 7 days, her Hb remained low and bilateral 
infiltrate still increased. That’s why we considered direct Coombs test and it returned positive. AIHA was diagnosed 
and treatment with hydrocortisone 100 mg IV twice daily was given for the first 72 h. The maintenance dose with 
methylprednisolone 16 mg twice daily was continued for 7 days admission. Then, Hb value increased to 11.03 g/dL 
and she was discharged home without any compliments. 
CONCLUSION: In the current epidemiological situation, AIHA needs to be considered as a complication 
of COVID-19 infection in a patient who presents with jaundice and severe anemia without any underlying chronic 
disease, which is need blood transfusions, steroid medication use, or blood cancer.
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Introduction
Unexplained pneumonia cases were reported 
by the People in Republic of China to the World Health 
Organization on December 31, 2019. This outbreak called 
coronavirus disease 2019 (COVID-19) that caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) [1]. Indonesian Ministry of Health reported the total 
number of COVID-19 cases in the world as of July 20, 2020, 
was confirmed as many as 14,043,176 cases and infected 
215 countries around the world. Of these, 597,583 people 
were reported dead. The mortality rate for COVID-19 in 
Indonesia is quite high (4.8%) when compared to the world 
average mortality rate of around 4.3% [2]. 
SARS-CoV-2 has spike protein which can 
strongly bound with an angiotensin-converting enzyme 
(ACE-2) in host cell. Mostly, ACE-2 is found in the lower 
respiratory tract, small bowel enterocyte, heart, vascular 
structure, and other parts of the body. That’s why this virus 
called thousand faces disease. The clinical manifestation 
is vary, could be asymptomatic, mild to severe, even 
mortality. Diabetes, cardiovascular disease, chronic 
lung disease, malignancy, immunosuppression, obesity, 
and elderly are high-risk comorbidities which can make 
poor prognosis of this infection. Laboratory levels of 
lymphopenia, thrombocytopenia, and elevated D-dimer 
levels are associated with severe disease [3], [4]. 
We report a novel case of Autoimmune Hemolytic 
Anemia (AIHA) as a complication of COVID-19 infection at 
our institution, Sanglah General Hospital, Bali, Indonesia. 
AIHA is a disorder caused by the presence of autoantibodies 
that attack normal erythrocyte membranes, which triggers 
the hemolysis process and results in a shortening of 
erythrocyte age (normal erythrocyte age ranges from 100 
to 120 days) [4], [5]. This condition exceeds the capacity of 
the bone marrow to produce new erythrocytes so that the 
level of reticulocytes in the blood will increase. The process 
of hemolysis can occur either inside the blood vessels 
(intravascular) or outside the blood vessels involving the 
reticuloendothelial system. The antigen on the erythrocyte 
membrane is recognized as foreign and destroyed in the 
spleen, liver, or bone marrow (extravascular) [6].
The incidence of AIHA reaches 1/100,000/year 
which can occur in all age groups, but the incidence 
increases with age. Diagnosis of AIHA is confirmed with 
a positive direct Coombs’ test (direct antiglobulin test 
[DAT]) [7]. 
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The mechanism of reducing hemoglobin (Hb) 
levels in COVID-19 patients is very limited. Liu et al. 
reported that the presence of spike-CD147 protein in 
the virus plays a role in the process of viral attachment 
to erythrocytes which causes the release of Hb from 
erythrocytes. The released Hb will be broken down 
into heme and globin. It reported that viral proteins 
such as Orflab, ORF3a, and ORF10 are able to bind to 
porphyrin in heme, which form a complex and causes 
the destruction of heme [8]. Angileri et al. also reported 
that molecular mimicry is thought to be a determinant 
factor in the incidence of AIHA in COVID-19 infection. 
Ankyrin-1 (ANK-1), a protein in the erythrocyte 
membrane, has the same antigenic epitope as the Spike 
protein in SARS-CoV-2 so that erythrocyte destruction 
is part of the patient’s immune defense mechanism 
which can cause a decrease in Hb levels [9].
The mechanism underpinning autoimmunity 
in COVID-19 which can cause hemolytic anemia by 
autoantibodies has yet to be elucidated. Besides that, 
corticosteroids are recommended to use in a patient 
with COVID-19 who are experiencing critical acute 
respiratory distress syndrome (ARDS). However, its 
administration is still controversial due to unwanted 
side effects such as secondary infection, complications 
of long-term use, and delayed viral load reduction [3]. 
On the other side, first-line therapy in AIHA cases 
emphasizes the use of corticosteroids to suppress 
autoimmunity processes that affect hemolysis [7]. Here, 
we present a complete response (CR) case of AIHA as 
a new complication in COVID-19 patient in Sanglah 
General Hospital, Bali, Indonesia
Case Report
A previously healthy 59-year-old woman, a 
shopkeeper, was admitted to our emergency room 
because of a 5-day period of fever with the cough. She 
also felt shortness of breath from one a week before 
admission, then worsen in 5 days. Changing position 
could not relieve the symptoms. Besides that, she also 
felt fatigue, nausea, and vomiting. Three days before 
admission, she also got jaundice in her eye and melena. 
The patient denied of suffering gall stone, kidney 
disease, or gastric ulcer before. She also did not have 
any history of disease, such as asthma, cancer, diabetes 
mellitus, hypertension, or tuberculosis. There was not 
any medication which she was consumed regularly. 
In the emergency room, she was tachypnea, 
tachycardia, and had an oxygen saturation of 60% 
on room air. Laboratory studies showed Hb 3.68 g/dL 
(13.5–17.5 g/dL) with microcytic hypochromic, leukocyte 
11.600/µL (4.100–11.000/µL), and high reticulocyte 
(14%). The value of SGOT is 106.4 U/L (11–27 U/L), 
SGPT is 60.90 U/L (11–34 U/L), ureum 17.7 mg/dL 
(8–23 mg/dL), and creatinine is about 0.79 mg/dL (0.5–
0.9 mg/dL). There was increment in bilirubin (total 
bilirubin 5.93 mg/dl; direct bilirubin 2.36 mg/dl, and 
indirect bilirubin 3.57 mg/dl). Besides that, prothrombin 
time/PT is 17.9 s (10–14.4 s) and activated partial 
thromboplastin time/APTT is 48.7 s (24–36 s). Feritin 
level as high as 6020 ng/mL (13–150 ng/mL) and total 
iron-binding capacity (TIBC) level is 228 g/dL (261–
478 g/dL). Other laboratory studies showed serum 
iron 144.1 g/dL (50–170 g/dL), alkaline phosphatase 
54 U/L (42–98 U/L), total protein 7.4 g/dL 
(6.4–8.3 g/dL), globulin 3.5 (3.2–3.7), and gamma-GT 
31 U/L (7–32  U/L). HBsAg test and Anti-HCV were non-
reactive. The chest X-ray showed bilateral pneumonia. 
Besides that, the polymerase chain reaction (PCR) test 
SARS-CoV-2 was positive through nasopharyngeal 
and oropharyngeal swab. 
Blood gas analysis reported that she got 
hypoxemic respiratory failure (type I) with uncompensated 
metabolic acidosis. Peripheral blood smear showed severe 
anisopoikilocytosis hypochromic with giant thrombocyte 
only, another parameter blood smear was normal. 
At admission, this patient got packed red cell 
(PRC) in 3 days and her hemoglobin increase becomes 
7.47 g/dL, but in 2 days later, her Hb decreases in 
6.35 g/dL. Transfusions were continued in 3 days later, 
so her Hb becomes 8.69 g/dL, but she felt fatigue and 
became more hypoxic, so she still dependent in oxygen 
supplementation. Her chest X-ray also showed much 
more infiltrate addition in both of her lungs than before. 
Because of this condition and the jaundice was still 
remained in her eyes, we considered to do serology 
test to see autoimmunity condition in this patient. Then, 
the results of direct Coombs test (DAT) were positive, 
and indirect Coombs test was negative. Hence, the 
diagnose of this patient was confirmed to be AIHA 
During admission, she was given oxygen using 
face mask, intravenous (IV) fluid drip, cefoperazone 1 
g IV twice a day, azithromycin 500 mg oral once daily, 
hyloquin 200 mg oral twice a day, acetylcysteine 200 
mg oral 3 times a day, and Vitamin C 500 mg oral twice 
a day. Besides that, she got hydrocortisone 100 mg 
IV twice a day at the first 72 h after she confirmed as 
AIHA. She relieved her symptoms such as weakness, 
pale skin, and tiredness; then, she got a maintenance 
dose of methylprednisolone 16 mg oral twice a day in 
the next 7 days of her admission. After this treatment, 
her Hb becomes 11.03 g/dL and she does not have any 
compliments so she could discharge home. 
Discussion
The COVID-19 pandemic has caused 
significant morbidity and mortality. The clinical 
manifestations of COVID-19 patients have a broad 
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spectrum, ranging from symptoms (asymptomatic), 
mild symptoms, pneumonia, severe pneumonia, ARDS, 
sepsis, to septic shock [10]. Manifested clinical anemia, 
many times, have been reported in COVID-19 patients 
with severe disease [11].
Patient 59-year-old woman, with a history 
5-day period of fever with cough, shortness of breath, 
felt fatigue, and she also got jaundice in her eye. There 
is no family history with hematology disease. Physical 
examination was tachypnea, tachycardia, and hypoxia. 
Laboratory studies showed severe anemia with high 
reticulocyte, increment in bilirubin, ferritin level, and 
TIBC level. Serum iron, alkaline phosphatase, total 
protein, globulin, and gamma GT was normal. The 
chest X-ray showed bilateral pneumonia. PCR test 
SARS-CoV-2 was positive through nasopharyngeal and 
oropharyngeal swab. Direct Coombs test was positive.
This patient is confirmed as COVID-19 based 
on the symptom in respiratory failure and positive 
results in PCR Test SARS COV-2. Recommendations 
from the First International Consensus Meeting reported 
about diagnostic criteria for AIHA are hemolysis sign 
accompanied by a positive DAT and exclusion of 
alternative causes [12]. In this patient, we got a sign 
of hemolysis such as jaundice, increment of hemolytic 
markers such as bilirubin and reticulocyte. Besides 
that, from the blood smear test, we found severe 
anisopoikilocytosis that shows hemolytic condition. 
Hence, she was confirmed to be AIHA through the 
positive result of DAT. 
Besides that, her iron blood test showed normal 
serum iron, increase in ferritin value, and TIBC value 
was decline which could be excluded iron deficiency 
anemia. She also did not have any history of chronic 
disease which is need medication regularly, so there 
was not any chronic disease or drug that induced her 
anemia. HBsAg test and anti-HCV were non-reactive, 
so anemia caused by hepatitis can be ruled out. There 
was no obvious provoking factor to her AIHA condition 
and thus it was attributed to her COVID-19 infection, 
being the first case reported so far in Bali, Indonesia. 
Our patient during 3 days of treatment since 
patient hospitalized, from May 24, 2020, to May 26, 
2020, the patient was given four bags of PRC blood 
transfusions (1.000 ml PRC), the Hb level increased 
from 3.68 g/dL to 7.47 g/dL, but the decrease in Hb 
levels occurred again on May 28, 2020, to 6.35 g/dL 
with persistent weakness and tightness so that patients 
still need oxygen supplementation. The patient was 
again given PRC transfusions from May 29, 2020, to 
May 31, 2020, as much as five bags of PRC (1.250 ml 
PRC), with an Hb level of 8.69 g/dL; the patient still 
complained of persistent tightness and chest X-ray 
evaluation showed additional infiltrates in both lung 
fields compared to the chest X-ray previously. During 
treatment, the patient showed no clinical improvement 
as well as an increase in Hb levels according to the 
transfusion target.
Anemia that occurs in patients is suspected to 
be due to the presence of a hemolysis process caused 
by autoimmunity so that the patient is subjected to 
direct Coombs test, and the result was positive. Since 
the patient is diagnosed with AIHA with COVID-19, the 
management using 100 mg of hydrocortisone steroid 
therapy every 12 h for 3 days intravenously starting 
on June 01, 2020–June 04, 2020. The patient has 
experienced improvement after being given steroids 
both clinically, laboratory, and radiologically so that 
it is continued by administering methylprednisolone 
16 mg every 12 h orally for 7 days of treatment. When 
discharged, the patient clinically had no complaints 
of respiration and laboratory results showed an 
improvement in Hb levels, bilirubin levels, and liver 
function. 
AIHA is characterized by the destruction of 
red blood cells by autoantibodies, but the mechanism 
underlying the autoimmunity of SARS-CoV-2 infection 
has yet to be explained. To the best of our knowledge, 
this is the first case report of COVID-19 with AIHA 
infection in Indonesia. In another case report, seven 
patients from six hospitals in France and Belgium 
reported the emergence of AHAI during COVID-19 
infection accompanied by previous comorbid diseases 
(hypertension, diabetes mellitus, and chronic renal 
failure). The mean time between the onset of Covid-19 
symptoms and the onset of AHAI was 9 days (range 4 
and 13 days) [11].
The mechanisms for reducing Hb levels in 
COVID-19 patients are very limited, two mechanisms 
currently reported are the Liu W and Angileri F 
studies in 2020. Liu et al. reported that the presence 
of spike-CD147 protein in the virus plays a role in the 
process of viral attachment to erythrocyte digestion and 
Angillery et al. reported that molecular mimicry ANK-1, 
a protein in the erythrocyte membrane, has the same 
antigenic epitope as the Spike protein in SARS-CoV-2 
so that erythrocyte destruction as part of the patient’s 
immune defense mechanism can cause a decrease in 
Hb levels [8], [9].
Liu et al. recently, it reports that the virus 
may first infect cells with ACE2 receptors, including 
immune cells. Immune cells produced antibodies and 
viral proteins. Antibodies and red blood cells generated 
immune hemolysis, or red blood cells were infected 
by Spike-CD147 pathway, by then, Hb was attached 
and then attacked produce toxic and inflammatory 
derivatives. This mechanism because of some viral 
proteins could combine to the porphyrin to form a 
complex, respectively. At the same time, orf1ab, 
ORF3a, and ORF10 proteins could coordinate attack 
the heme on Hb. Deoxyhemoglobin is more vulnerable 
to virus attacks than oxidized Hb. The attack will lead to 
less Hb to carry oxygen and carbon dioxide. Lung cells 
are toxic and inflammatory due to derivatives produced 
by the attack, which eventually resulted in ground 
glass appearance. Capillaries easily were broken due 
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to inflammation. Proteins such as fibrinogen fill the 
capillaries cracks through the coagulation reaction [8]. 
Angilleri e.al. reported the hypothesis that 
molecular mimicry ANK-1, a protein in the erythrocyte 
membrane, has the same antigenic epitope as the Spike 
protein in SARS-CoV-2 so that erythrocyte destruction 
as part of the patient’s immune defense mechanism can 
cause a decrease in Hb levels. ANK-1 is an erythrocyte 
membrane protein for red cell differentiation and 
function, providing the primary connection between 
the membrane skeleton and the plasma membrane. 
They found that ANK-1 shares a putative immunogenic-
antigenic epitope (amino acids LLLQY) with 100% 
identity with the SARS-CoV-2 surface glycoprotein 
named Spike protein. They are established that this 
epitope is part of Spike’s predicted immunogenic 
epitope 750-SNLLLQYGSFCTQL-763 for B cells using 
the immune epitope database and analysis resource [9].
Steroid administration in COVID-19 is given 
in accordance when a hypoxic condition occurs in the 
patient. Giving anti-inflammatory therapy too early is not 
recommended because it can inhibit the development 
of adaptive immune responses and even trigger viral 
replication [13]. This is in line with research by Lee 
et al. who reported that administration of corticosteroid 
therapy early in Coronavirus infection is associated 
with an increase in plasma viral load and should be 
avoided [14]. Steroids such as dexamethasone 6 mg 
given for 10 days indicated only for patients with 
acute hypoxemic respiratory failure (increased oxygen 
demand), requires mechanical ventilation, as well as in 
conditions that support the need for steroids (e.g., asthma 
with chronic obstructive pulmonary disease [COPD] and 
COPD exacerbations). Other corticosteroids that can 
be an option in the equivalent dose are betamethasone 
oral 6 mg, methylprednisolone oral or injection 32 mg, 
and prednisone or prednisolone 40 mg oral [15]. The 
recommended dose is hydrocortisone 200 mg/24 h or 
its equivalent, given in conditions of refractory shock 
or signs of ARDS. The administration of corticosteroid 
therapy is proven to provide benefits in the development 
of the patient’s condition so that the patient can avoid 
worsening that requires mechanical ventilation and 
achieve a CR in conditions of AIHA. Since corticosteroid 
can make false negative in direct Coombs test (DAT), it 
suggested that direct Coombs test should be performed 
before corticosteroid administration.
Conclusion
To the best of our knowledge, this is the first 
case report SARS CoV-2 could have triggered AIHA in 
adult in Bali, Indonesia. Her workup for other etiologies, 
including other diseases or another viral infection that 
causes hemolytic condition was unrevealing. During 
this current COVID-19 pandemic, it is necessary to 
consider the presence AIHA as new complications in 
COVID-19 infection. Hence, it is deemed necessary to 
carry out a DAT to rule out complications of AIHA in 
COVID-19 patients who present anemia accompanied 
by evidence of hemolysis to provide comprehensive 
therapy of the patient.
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